Recruiting
Acute lymphocytic leukaemia recurrent+5
RecruitingLong-Term Safety Study of MB-CART19.1, MB-CART20.1, and Zamtocabtagene Autoleucel for Patients with Advanced Melanoma or B-Cell Malignancies
InvestigationalNo placebo
Long-Term Safety Study of MB-CART19.1, MB-CART20.1, and Zamtocabtagene Autoleucel for Patients with Advanced Melanoma or B-Cell Malignancies
InvestigationalNo placebo
- Disease:Acute lymphocytic leukaemia recurrentChronic lymphocytic leukaemia refractory+4
- Substances:Mb-Cart20.1Autologous T-Cells Transduced With Lentiviral Vector Expressing A Chimeric Antigen Receptor Directed Against Cd19+1
Countries:
Germany
Germany- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Mb-Cart20.1